MoonLake Immunotherapeutics (MLTX) 10-Year Financial Performance & Capital Metrics

MLTX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutMoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.Show more

Revenue $0
EBITDA -$142M -163.6%
Net Income -$119M -230.3%
EPS (Diluted) -1.89 -158.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -24.6% -98.9%
ROIC -62.79% +26.1%
Debt/Equity 0.01 -13.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 19 (bottom 19%)
✗Shares diluted 28.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-160.62%

EPS CAGR

10Y-

5Y-

3Y-

TTM-157.36%

ROCE

10Y Avg-75.04%

5Y Avg-75.04%

3Y Avg-91.05%

Latest-29.44%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	2.01B	15.23	387.53	33.97%	29.28%	21.28%	2.2%	0.21
ARGXargenx SE	49.47B	799.33	62.55	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.74	54.83	15.54%	32.78%	12.61%	12.77%	0.65
GLPGGalapagos N.V.	2.25B	34.12	30.46	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.33B	85.23	20.15	6.24%	21.94%	7.11%	3.43%	0.02
ALMSAlumis Inc. Common Stock	2.86B	24.34	-2.34		-11.08%	-63.71%		0.12
ZBIOZenas BioPharma, Inc.	1.21B	22.56	-6	-90%	-12.66%	-96.68%		0.00
ORKAOruka Therapeutics, Inc.	1.55B	32.00	-6.41			-22.44%		0.00

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	4.97K	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	-4.97K	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	1%	-	-
Operating Expenses+	105.75K	53.57M	65.06M	54.12M	143.09M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	105.75K	18.05M	23.01M	22.32M	30.32M
SG&A % of Revenue	-	-	-	-	-
Research & Development	0	35.52M	42.05M	31.8M	112.77M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-105.75K	-53.58M	-65.06M	-54.12M	-143.09M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-505.61%	-0.21%	0.17%	-1.64%
EBITDA+	-90.84K	-53.57M	-64.9M	-53.75M	-141.71M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-588.75%	-0.21%	0.17%	-1.64%
D&A (Non-Cash Add-back)	0	4.97K	164.78K	370.32K	1.38M
EBIT	-90.84K	-53.64M	-65.06M	-54.12M	-143.09M
Net Interest Income+	14.92K	0	0	0	0
Interest Income	14.92K	0	0	0	0
Interest Expense	0	0	0	0	0
Other Income/Expense	14.92K	-61.85K	591.73K	10.14M	22.13M
Pretax Income+	-90.84K	-53.64M	-64.47M	-43.98M	-120.96M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	4.75K	36.37K	94.39K	282.2K
Effective Tax Rate %	1%	1%	0.78%	0.82%	0.98%
Net Income+	-90.84K	-53.64M	-49.97M	-36.01M	-118.94M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-589.54%	0.07%	0.28%	-2.3%
Net Income (Continuing)	-90.84K	-53.64M	-64.51M	-44.08M	-121.24M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	19.87M	17.82M	6.57M
EPS (Diluted)+	-0.01	-1.45	-2.20	-0.73	-1.89
EPS Growth %	-	-	-0.52%	0.67%	-1.59%
EPS (Basic)	-0.01	-1.45	-2.20	-0.73	-1.89
Diluted Shares Outstanding	14.8M	36.93M	29.36M	49.12M	62.87M
Basic Shares Outstanding	14.8M	36.93M	29.36M	49.12M	62.87M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.62M	9.64M	76.51M	514.17M	474.29M
Cash & Short-Term Investments	1.34M	8.04M	72.11M	511.01M	448.03M
Cash Only	1.34M	8.04M	39.51M	451.17M	180.43M
Short-Term Investments	0	0	32.61M	59.84M	267.6M
Accounts Receivable	0	148.77K	217.13K	1.06M	2.84M
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	0	0	0
Total Non-Current Assets+	115.01M	45.74K	331.97K	12.37M	3.64M
Property, Plant & Equipment	0	45.74K	331.97K	3.95M	3.64M
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	115.01M	115.04M	0	0	0
Other Non-Current Assets	0	-115.04M	0	8.42M	0
Total Assets+	116.63M	9.68M	76.84M	526.54M	477.93M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	-0.92%	6.94%	5.85%	-0.09%
Total Current Liabilities+	125.18K	21.09M	7.67M	9.97M	22.46M
Accounts Payable	0	1.23M	47.48K	1.46M	8.68M
Days Payables Outstanding	-	90.54K	-	-	-
Short-Term Debt	58.06K	15M	0	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	67.12K	1.3M	109.83K	2.78M	4.24M
Current Ratio	12.93x	0.46x	9.98x	51.59x	21.11x
Quick Ratio	12.93x	0.46x	9.98x	51.59x	21.11x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	4.03M	239.86K	411.16K	3.08M	2.08M
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	128.95K	2.5M	1.46M
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	4.03M	239.86K	282.21K	583.43K	620.68K
Total Liabilities	4.15M	21.33M	8.08M	13.05M	24.54M
Total Debt+	58.06K	15M	282.58K	3.7M	2.83M
Net Debt	-1.28M	6.96M	-39.22M	-447.47M	-177.6M
Debt / Equity	0.00x	-	0.00x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-	-	-
Total Equity+	112.48M	-11.65M	68.77M	513.49M	453.39M
Equity Growth %	-	-1.1%	6.91%	6.47%	-0.12%
Book Value per Share	7.60	-0.32	2.34	10.45	7.21
Total Shareholders' Equity	112.48M	-11.65M	48.9M	495.68M	446.83M
Common Stock	115M	38.54K	5.27K	6.3K	6.39K
Retained Earnings	-2.52M	-53.64M	-80.65M	-116.66M	-235.59M
Treasury Stock	0	-6.2K	0	0	0
Accumulated OCI	0	-168.18K	350.95K	2.36M	5M
Minority Interest	0	0	19.87M	17.82M	6.57M

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-316.69K	-35.18M	-55.89M	-42.78M	-116.59M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-110.07%	-0.59%	0.23%	-1.73%
Net Income	-90.84K	-53.64M	-49.97M	-44.08M	-121.24M
Depreciation & Amortization	0	4.97K	12.36K	13.16K	1.38M
Stock-Based Compensation	0	0	0	7.11M	7.28M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	-9.92K	13.98M	-4.51M	399.51K	-225.71K
Working Capital Changes	-215.94K	4.48M	-1.43M	-6.22M	-3.78M
Change in Receivables	0	-148.77K	-68.36K	0	-1.79M
Change in Inventory	0	0	0	0	0
Change in Payables	0	1.57M	-1.31M	0	0
Cash from Investing+	-115M	-50.71K	-32.34M	-25.18M	-205.6M
Capital Expenditures	0	-50.71K	-16.01K	-284.63K	-519.52K
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	116.65M	43.26M	119.69M	479.7M	51.31M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	-347.38K	0	134.69M	-2.75M	-1.23M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-316.69K	-35.23M	-55.91M	-43.06M	-117.11M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-110.23%	-0.59%	0.23%	-1.72%
FCF per Share	-0.02	-0.95	-1.90	-0.88	-1.86
FCF Conversion (FCF/Net Income)	3.49x	0.66x	1.12x	1.19x	0.98x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	41.71K	147.29K

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.08%	-106.39%	-174.97%	-12.37%	-24.6%
Return on Invested Capital (ROIC)	-	-75.44%	-392.57%	-84.95%	-62.79%
Debt / Equity	0.00x	-	0.00x	0.01x	0.01x
FCF Conversion	3.49x	0.66x	1.12x	1.19x	0.98x

Revenue by Segment

	2022	2023	2024
License	299.6M	299.6M	299.6M
License Growth	-	0.00%	0.00%

Frequently Asked Questions

Growth & Financials

MoonLake Immunotherapeutics (MLTX) grew revenue by 0.0% over the past year. Growth has been modest.

MoonLake Immunotherapeutics (MLTX) reported a net loss of $210.5M for fiscal year 2024.

Dividend & Returns

MoonLake Immunotherapeutics (MLTX) has a return on equity (ROE) of -24.6%. Negative ROE indicates the company is unprofitable.

MoonLake Immunotherapeutics (MLTX) had negative free cash flow of $185.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener